A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Status:
Recruiting
Trial end date:
2025-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of MK-6194 in
participants with non-segmental vitiligo. The primary hypothesis is that at least 1 MK-6194
dose is superior to placebo with regards to percent change from baseline in Facial Vitiligo
Area Scoring Index (F-VASI) at Week 24.